Markers of mineral metabolism and vascular access complications: The Choices for Healthy Outcomes in Caring for ESRD (CHOICE) study

Ali I Gardezi, Muhammad S Karim, Joel E Rosenberg, Julia J Scialla, Tanushree Banerjee, Neil R Powe, Tariq Shafi, Rulan S Parekh, Alexander S Yevzlin, Brad C Astor, Ali I Gardezi, Muhammad S Karim, Joel E Rosenberg, Julia J Scialla, Tanushree Banerjee, Neil R Powe, Tariq Shafi, Rulan S Parekh, Alexander S Yevzlin, Brad C Astor

Abstract

Introduction: Vascular access dysfunction is a major cause of morbidity in patients with end-stage renal disease (ESRD) on chronic hemodialysis. The effects of abnormalities in mineral metabolism on vascular access are unclear. In this study, we evaluated the association of mineral metabolites, including 25-hydroxy vitamin D (25(OH)D) and fibroblast growth factor-23 (FGF-23), with vascular access complications.

Methods: We included participants from the Choices for Healthy Outcomes in Caring for ESRD (CHOICE) Study who were using an arteriovenous fistula (AVF; n = 103) or arteriovenous graft (AVG; n = 116). Serum levels of 25(OH)D, FGF-23, parathyroid hormone (PTH), calcium, phosphorus, C-reactive protein (CRP) and interleukin-6 (IL-6) were assessed from stored samples. Participants were followed for up to 1 year or until a vascular access intervention or replacement.

Findings: A total of 24 participants using an AVF and 43 participants using an AVG experienced access intervention. Those with 25(OH)D level in the lowest tertile (<11 ng/mL) had an increased risk of AVF intervention compared to those with higher 25(OH)D levels (adjusted relative hazard [aHR] = 3.28; 95% confidence interval [CI]: 1.31, 8.20). The highest tertile of FGF-23 (>3750 RU/mL) was associated with greater risk of AVF intervention (aHR = 2.56; 95% CI: 1.06, 6.18). Higher PTH was associated with higher risk of AVF intervention (aHR = 1.64 per SD of log(PTH); 95% CI: 1.02, 2.62). These associations were not observed in participants using an AVG. None of the other analytes were significantly associated with AVF or AVG intervention.

Discussion: Low levels of 25(OH)D and high levels of FGF-23 and PTH are associated with increased risk of AVF intervention. Abnormalities in mineral metabolism are risk factors for vascular access dysfunction and potential therapeutic targets to improve outcomes.

Keywords: FGF-23; Mineral metabolism; PTH; Vascular access; Vitamin D25.

© 2019 International Society for Hemodialysis.

References

    1. Feldman HI, Kobrin S, Wasserstein A. Hemodialysis vascular access morbidity. J Am Soc Nephrol. 1996;7:523-535.
    1. Rayner HC, Pisoni RL, Bommer J, et al. Mortality and hospitalization in haemodialysis patients in five European countries: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:108-120.
    1. Rosenberg JE, Astor BC, Deluca HF, Yevzlin AS. The association of mineral metabolism with vascular access patency. J Vasc Access. 2016;17:392-396.
    1. Navarro-González JF, Mora-Fernández C, Muros M, Herrera H, García J. Mineral metabolism and inflammation in chronic kidney disease patients: A cross-sectional study. Clin J Am Soc Nephrol. 2009;4:1646-1654.
    1. Scialla JJ, Parekh RS, Eustace JA, et al. Race, mineral homeostasis and mortality in patients with end-stage renal disease on dialysis. Am J Nephrol. 2015;42:25-34.
    1. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients. A national study. Am J Kidney Dis. 1998;31:607-617.
    1. Melamed ML, Astor B, Michos ED, Hostetter TH, Powe NR, Muntner P. 25-hydroxyvitamin D levels, race, and the progression of kidney disease. J Am Soc Nephrol. 2009;20:2631-2639.
    1. Melamed ML, Eustace JA, Plantinga L, et al. Changes in serum calcium, phosphate, and PTH and the risk of death in incident dialysis patients; a longitudinal study. Kidney Int. 2006;70:351-357.
    1. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359:584-592.
    1. Korkor AB, Bretzmann CM, Eastwood DC. Vitamin D deficiency in dialysis patients and its effect on various disease markers. Dial Transplant. 2009;38:461-464.
    1. Zhang Y, Darssan D, Pascoe EM, Johnson DW, Pi H, Dong J. Vitamin D status and mortality risk among patients on dialysis: A systematic review and meta-analysis of observational studies. Nephrol Dial Transplant. 2018;33:1742-1751.
    1. London GM, Guérin AP, Verbeke FH, et al. Mineral metabolism and arterial functions in end-stage renal disease; potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol. 2007;18:613-620.
    1. Powe NR, Klag MJ, Sadler JH, et al. Choices for healthy outcomes in caring for end stage renal disease. Semin Dial. 1996;9:9-11.
    1. Athienites NV, Miskulin DC, Fernandez G, et al. Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent disease. Semin Dial. 2000;13:320-326.
    1. Nicolucci A, Cubasso D, Labbrozzi D, et al. Effect of coexistent diseases on survival of patients undergoing dialysis. ASAIO J. 1992;38:M291-M295.
    1. Abe M, Okada K, Soma M. Mineral metabolic abnormalities and mortality in dialysis patients. Nutrients. 2013;5:1002-1023.
    1. Walker J, Hiramoto J, Gasper W, et al. Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end stage renal disease. J Vasc Surg. 2014;60:176-183.
    1. Morena M, Bosc JY, Jaussent I, et al. The role of mineral metabolism and inflammation on dialysis vascular access failure. J Vasc Access. 2006;7:77-82.
    1. Filho AJI, Malamed ML. Vitamin D and kidney disease. What we know and what we do not know. J Bras Nefrol. 2013;35:323-331.
    1. Liu S, Tang W, Zhou J, et al. Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol. 2006;17:1305-1315.
    1. Kovesdey CP, Quarles LD. Fibroblast growth factor-23: What we know, what we don't know, and what we need to know. Nephrol Dial Transplant. 2013;28:2228-2236.
    1. Matias PJ, Jorge C, Ferreira C, et al. Cholecalciferol supplementation in hemodialysis patients: Effects on mineral metabolism, inflammation, and cardiac dimension parameters. Clin J Am Soc Nephrol. 2010;5:905-911.
    1. Stenvinkel P, Ketteler M, Jonhson RJ, et al. IL-10, IL-6, and TNF-a: Central factors in the altered cytokine network of uremia-The good, the bad, and the ugly. Kidney Int. 2005;67:1216-1233.
    1. Panichi V, Taccola D, Rizza GM, et al. Interleukin-8 is a powerful prognostic predictor of all-cause and cardiovascular mortality in dialytic patients. Nephron Clin Pract. 2006;102:c51-c58.
    1. Stubbs JR, Idiculla A, Slusser J, Menard R, Quarles LD. Cholecalciferol supplementation alters calcitriol responsive monocyte proteins and decreases inflammatory cytokines in ESRD. J Am Soc Nephrol. 2010;21:353-361.
    1. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1a-hydroxylase knockout mice. Kidney Int. 2008;74:170-179.
    1. Chitalia N, Recio-Mayorel A, Kaski JC, Banerjee D. Vitamin D deficiency and endothelial dysfunction in non-dialysis chronic kidney disease patients. Atherosclerosis. 2012;220:265-268.
    1. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2004 Mar;19:429-435.
    1. Dai B, David V, Martin A, et al. A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012;7:e44161.
    1. Wasse H, Huang R, Long Q, et al. Very high-dose cholecalciferol and arteriovenous fistula maturation in ESRD: A randomized, double-blind, placebo-controlled pilot study. J Vasc Access. 2014;15:88-94.
    1. Goodman WG. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease. Semin Dial. 2004;17:209-216.
    1. Rostand SG, Drueke TB. Parathyroid hormone, vitamin D, and cardiovascular disease in chronic renal failure. Kidney Int. 1999;56:383-392.
    1. Sato T, Iwasaki Y, Kikkawa Y, Fukagawa M. An efficacy of intensive vitamin D delivery to neointimal hyperplasia in recurrent vascular access stenosis. J Vasc Access. 2016;17:72-77.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다